Formulation of a kit under Good Manufacturing Practices (GMP) for preparing [ 111 In]In-BnDTPA-trastuzumab-NLS injection: a theranostic agent for imaging and Meitner-Auger Electron (MAE) radioimmunotherapy of HER2-positive breast cancer.
Conrad ChanVanessa ProzzoSadaf AghevlianRaymond M ReillyPublished in: EJNMMI radiopharmacy and chemistry (2022)
In[In]-BnDTPA-trastuzumab-NLS injection. This radiopharmaceutical was safely administered to 4 patients with HER2-positive BC to trace the uptake of trastuzumab into brain metastases before and after MRI-guided focused ultrasound (MRIg-FUS) by SPECT imaging.
Keyphrases
- positive breast cancer
- brain metastases
- epidermal growth factor receptor
- high resolution
- small cell lung cancer
- metastatic breast cancer
- healthcare
- primary care
- magnetic resonance imaging
- fluorescence imaging
- ultrasound guided
- photodynamic therapy
- drug delivery
- contrast enhanced
- computed tomography
- heavy metals
- pet ct
- magnetic resonance
- tyrosine kinase
- escherichia coli
- mass spectrometry
- biofilm formation
- staphylococcus aureus
- candida albicans